Rezolute (RZLT) Equity Average (2011 - 2026)
Rezolute recorded quarterly Equity Average of $122.4 million in Q1 2026, down 11.02% quarter-over-quarter from $137.6 million in Q4 2025, and up 34.41% year-over-year from $91.1 million in Q1 2025.
Rezolute's Equity Average history runs 16 years deep, the most recent figure standing at $122.4 million for Q1 2026.
- In Q1 2026, Equity Average rose 34.41% year-over-year to $122.4 million; the TTM figure through Mar 2026 stood at $122.4 million (up 34.41% YoY), while the FY2025 annual figure was $141.6 million, up 19.38% from the prior year.
- Equity Average came in at $122.4 million for Q1 2026 at Rezolute, down from $137.6 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $154.6 million in Q3 2025 to a low of $57.1 million in Q1 2022.
- A 5-year average of $114.6 million and a median of $117.2 million in 2024 frame the typical range for Equity Average.
- Across the five-year window, Equity Average jumped 534.86% in 2022 and tumbled 39.46% in 2024, its largest moves.
- Rezolute's Equity Average stood at $147.2 million in 2022, then tumbled by 33.65% to $97.6 million in 2023, then advanced by 9.08% to $106.5 million in 2024, then gained by 29.17% to $137.6 million in 2025, then retreated by 11.02% to $122.4 million in 2026.
- According to Business Quant data, Equity Average over the past three periods registered $122.4 million, $137.6 million, and $154.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 122.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122.42 Mn |
| Dec 31, 2025 | 137.58 Mn |
| Sep 30, 2025 | 154.65 Mn |
| Jun 30, 2025 | 122.35 Mn |
| Mar 31, 2025 | 91.08 Mn |
| Dec 31, 2024 | 106.52 Mn |
| Sep 30, 2024 | 117.22 Mn |
| Jun 30, 2024 | 95.93 Mn |
| Mar 31, 2024 | 81.29 Mn |
| Dec 31, 2023 | 97.65 Mn |
| Sep 30, 2023 | 109.87 Mn |
| Jun 30, 2023 | 121.74 Mn |
| Mar 31, 2023 | 134.29 Mn |
| Dec 31, 2022 | 147.18 Mn |
| Sep 30, 2022 | 151.28 Mn |
| Jun 30, 2022 | 100.69 Mn |
| Mar 31, 2022 | 57.09 Mn |
| Dec 31, 2021 | 41.91 Mn |
| Sep 30, 2021 | 23.83 Mn |
| Jun 30, 2021 | 27.62 Mn |
| Mar 31, 2021 | 32.51 Mn |
| Dec 31, 2020 | 20.13 Mn |
| Sep 30, 2020 | 5.87 Mn |
| Jun 30, 2020 | 8.85 Mn |
| Mar 31, 2020 | 12.51 Mn |
| Dec 31, 2019 | 17.65 Mn |
| Sep 30, 2019 | 11.19 Mn |
| Jun 30, 2019 | 3.20 Mn |
| Mar 31, 2019 | -2.57 Mn |
| Dec 31, 2018 | -8.12 Mn |
| Sep 30, 2018 | -5.20 Mn |
| Jun 30, 2018 | -1.71 Mn |
| Mar 31, 2018 | 2.17 Mn |
| Dec 31, 2017 | 5.80 Mn |
| Sep 30, 2017 | 8.17 Mn |
| Jun 30, 2017 | 8.49 Mn |
| Mar 31, 2017 | 8.20 Mn |
| Dec 31, 2016 | 8.07 Mn |
| Sep 30, 2016 | 8.49 Mn |
| Jun 30, 2016 | 4.95 Mn |
| Mar 31, 2016 | 2.45 Mn |
| Dec 31, 2015 | 5.27 Mn |
| Sep 30, 2015 | 7.91 Mn |
| Jun 30, 2015 | 9.38 Mn |
| Mar 31, 2015 | 8.76 Mn |
| Dec 31, 2014 | 6.42 Mn |
| Sep 30, 2014 | 5.71 Mn |
| Jun 30, 2014 | 4.91 Mn |
| Mar 31, 2014 | -494,464.00 |
| Dec 31, 2013 | -4.61 Mn |
| Sep 30, 2013 | -4.49 Mn |
| Jun 30, 2013 | -3.86 Mn |
| Mar 31, 2013 | -1.79 Mn |
| Dec 31, 2012 | -19,816.50 |
| Sep 30, 2012 | -652,038.00 |
| Jun 30, 2012 | -644,438.50 |
| Mar 31, 2012 | -445,334.00 |
| Dec 31, 2011 | -436,362.50 |
| Sep 30, 2011 | -243,775.50 |